1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )-Pipeline Insights, 2016


DelveInsight’s, “ Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ). The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ). DelveInsight’s Report also assesses the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitivepipeline landscape of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )-Pipeline Insights, 2016

Illustrative Table of contents

- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Overview
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Pipeline Therapeutics
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics under Development by Companies
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Filed and Phase III Products
- Comparative Analysis
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Phase II Products
- Comparative Analysis
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Phase I and IND Filed Products
- Comparative Analysis
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Discontinued Products
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Dormant Products
- Companies Involved in Therapeutics Development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Assessment by Monotherapy Products
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Assessment by Combination Products
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Assessment by Route of Administration
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Assessment by Stage and Route of Administration
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Assessment by Molecule Type
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Assessment by Stage and Molecule Type
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics - Discontinued Products
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Assessment by Monotherapy Products
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Assessment by Combination Products
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Assessment by Route of Administration
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Assessment by Stage and Route of Administration
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Assessment by Molecule Type
- Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Mucopolysaccharidosis-Market Insights, Epidemiology and Market Forecast-2023

Mucopolysaccharidosis-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Mucopolysaccharidosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023

Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023

Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...


Download Unlimited Documents from Trusted Public Sources

Endocrine Disease Statistics in the US

  • November 2016
    14 pages
  • Endocrine Disea...  

    Therapy  

  • United States  

View report >

Diabetes Statistics and Endocrine Disease Statistics in the US

  • October 2016
    176 pages
  • Diabetes  

    Type 1 Diabetes  

    Endocrine Disea...  

  • United States  

View report >

Pathology Statistics in South Africa and Africa

  • October 2016
    7 pages
  • Type 1 Diabetes  

  • South Africa  

    Africa  

View report >

Global Aids Statistics

2 months ago

Related Market Segments :

Endocrine Disease

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.